Clinical Trial Update: DEC-C and Thioguanine for R/R AML [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating DEC-C (decitabine/cedazuridine) and Thioguanine for relapsed/refractory acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DEC-C (decitabine/cedazuridine)
• Thioguanine (thioguanine)

Snippet

Sponsor: Columbia University | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: WITHDRAWN